ID

15860

Description

Micro RNAs to Predict Response to Androgen Deprivation Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT02366494

Link

https://clinicaltrials.gov/show/NCT02366494

Keywords

Versions (1)
  1. 6/16/16 6/16/16 -
Uploaded on

June 16, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Prostate Cancer NCT02366494

English

Eligibility Prostate Cancer NCT02366494

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically proven prostate cancer.
Description

prostate cancer

Data type

boolean

Alias
UMLS CUI [1]
C0600139
testosterone level >30ng/ml and at least 6 months since last dose of hormonal therapy.
Description

Testosterone measurement | Hormone Therapy

Data type

boolean

Alias
UMLS CUI [1]
C0523912
UMLS CUI [2]
C0279025
history/physical examination including a detailed description of the stage of prostate cancer within 8 weeks prior to registration.
Description

Physical Examination | Prostate carcinoma | TNM clinical staging

Data type

boolean

Alias
UMLS CUI [1]
C0031809
UMLS CUI [2]
C0600139
UMLS CUI [3]
C3258246
ct scan of abdomen and pelvis with iv contrast and bone scan should be performed within 8 weeks prior to registration.
Description

CT with intravenous contrast Abdomen | CT with intravenous contrast Pelvis | Radioisotope scan of bone

Data type

boolean

Alias
UMLS CUI [1,1]
C0202653
UMLS CUI [1,2]
C0000726
UMLS CUI [2,1]
C0202653
UMLS CUI [2,2]
C0030797
UMLS CUI [3]
C0203668
ecog performance status 0-2.
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
age ≥ 18.
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
patients must provide study-specific informed consent prior to study entry for this project and mandatory blood specimen for banking for future studies (future studies may include genetic testing).
Description

Informed Consent | Blood specimen Requirement | BLOOD BANKING | Genetic testing

Data type

boolean

Alias
UMLS CUI [1]
C0021430
UMLS CUI [2,1]
C0178913
UMLS CUI [2,2]
C1514873
UMLS CUI [3]
C0200495
UMLS CUI [4]
C0679560
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
received hormonal therapy less than 6 months prior to registration.
Description

Hormone Therapy

Data type

boolean

Alias
UMLS CUI [1]
C0279025
history of active secondary malignancy.
Description

Secondary Malignant Neoplasm

Data type

boolean

Alias
UMLS CUI [1]
C3266877
decline hormone therapy for prostate cancer.
Description

Prostate carcinoma | Hormone Therapy Refused

Data type

boolean

Alias
UMLS CUI [1]
C0600139
UMLS CUI [2,1]
C0279025
UMLS CUI [2,2]
C1705116
current or previous treatment with 5-alpha reductase inhibitors within 6 months prior to enrollment.
Description

Therapeutic procedure 5-alpha Reductase Inhibitors

Data type

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C2936788
Back to the top of the page

Similar models

Eligibility Prostate Cancer NCT02366494

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
prostate cancer
Item
histologically proven prostate cancer.
boolean
C0600139 (UMLS CUI [1])
Testosterone measurement | Hormone Therapy
Item
testosterone level >30ng/ml and at least 6 months since last dose of hormonal therapy.
boolean
C0523912 (UMLS CUI [1])
C0279025 (UMLS CUI [2])
Physical Examination | Prostate carcinoma | TNM clinical staging
Item
history/physical examination including a detailed description of the stage of prostate cancer within 8 weeks prior to registration.
boolean
C0031809 (UMLS CUI [1])
C0600139 (UMLS CUI [2])
C3258246 (UMLS CUI [3])
CT with intravenous contrast Abdomen | CT with intravenous contrast Pelvis | Radioisotope scan of bone
Item
ct scan of abdomen and pelvis with iv contrast and bone scan should be performed within 8 weeks prior to registration.
boolean
C0202653 (UMLS CUI [1,1])
C0000726 (UMLS CUI [1,2])
C0202653 (UMLS CUI [2,1])
C0030797 (UMLS CUI [2,2])
C0203668 (UMLS CUI [3])
ECOG performance status
Item
ecog performance status 0-2.
boolean
C1520224 (UMLS CUI [1])
Age
Item
age ≥ 18.
boolean
C0001779 (UMLS CUI [1])
Informed Consent | Blood specimen Requirement | BLOOD BANKING | Genetic testing
Item
patients must provide study-specific informed consent prior to study entry for this project and mandatory blood specimen for banking for future studies (future studies may include genetic testing).
boolean
C0021430 (UMLS CUI [1])
C0178913 (UMLS CUI [2,1])
C1514873 (UMLS CUI [2,2])
C0200495 (UMLS CUI [3])
C0679560 (UMLS CUI [4])
Item Group
C0680251 (UMLS CUI)
Hormone Therapy
Item
received hormonal therapy less than 6 months prior to registration.
boolean
C0279025 (UMLS CUI [1])
Secondary Malignant Neoplasm
Item
history of active secondary malignancy.
boolean
C3266877 (UMLS CUI [1])
Prostate carcinoma | Hormone Therapy Refused
Item
decline hormone therapy for prostate cancer.
boolean
C0600139 (UMLS CUI [1])
C0279025 (UMLS CUI [2,1])
C1705116 (UMLS CUI [2,2])
Therapeutic procedure 5-alpha Reductase Inhibitors
Item
current or previous treatment with 5-alpha reductase inhibitors within 6 months prior to enrollment.
boolean
C0087111 (UMLS CUI [1,1])
C2936788 (UMLS CUI [1,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial